Background {#Sec1}
==========

Critically ill patients frequently experience stress-induced alterations in glucose homoeostasis resulting in hyperglycemia \[[@CR1]\]. Peripheral insulin resistance and an enhanced hepatic glucose production, caused by a release of counter-regulatory hormones and cytokines, are contributing mechanisms \[[@CR1], [@CR2]\]. Insufficient GLUT4 translocation in skeletal muscle of critically ill patients is related to glucose dysregulation \[[@CR3]\]. Hyperglycemia, elevated glycemic variability and hypoglycemia, were associated with an increased mortality risk in critically ill patients \[[@CR4]--[@CR6]\]. Randomized controlled trials showed that insulin therapy and management of glycemic control in the ICU remains challenging \[[@CR6]--[@CR10]\].

Continuous glucose monitoring (CGM) in the ICU, combined with an appropriate insulin protocol, may improve management of glycemic control and consequently impact patient outcome \[[@CR11]--[@CR13]\]. Wernerman et al. provided an overview of CGM technologies, including glucose oxidase, mid-infrared spectroscopy and fluorescence, ranging from invasive intravascular devices to minimally invasive interstitial and noninvasive transcutaneous systems \[[@CR11]\]. Interstitial devices designed for use in diabetic patients have already been applied in critically ill patients \[[@CR13]--[@CR16]\]. Despite promising attempts, these systems have not yet been implemented to daily routine in the ICU and improvements are desirable. The subcutaneous Medtronic Sentrino^®^ CGM system was designed for use in ICU patients. The displayed real-time glucose trend line allows the ICU staff to observe glucose excursions at an earlier stage when compared to the established intermittent measurements. Patients may benefit from increased time in target range and improved glycemic variability. In addition, nurse workload may be reduced.

The purpose of this study was to evaluate reliability, feasibility, nurse acceptance and accuracy of this subcutaneous CGM system, as well as to identify potential weaknesses of the device in severely ill patients. In addition to previous studies \[[@CR17]--[@CR19]\], we retrospectively assessed potential benefits of CGM in comparison with intermittent glucose monitoring in our medical-surgical ICU.

Methods {#Sec2}
=======

Inclusion criteria and study participants {#Sec3}
-----------------------------------------

Inclusion criteria included an expected length of stay in the ICU of at least 72 h, age ≥18 years and written informed consent given by patient or legal proxy. We recruited critically ill patients during a time period of seven months in 2014. Patient inclusion started immediately after the local ethics committee, Ethikkommission Charité Universitätsmedizin Berlin, approved the study protocol (Charité-EA2/095/14). The protocol was registered under <https://clinicaltrials.gov>, trial registration number NCT02296372.

Glycemic control in the study setting {#Sec4}
-------------------------------------

The single-center study was set in two interdisciplinary mixed medical-surgical ICUs of a university hospital. The glucose target levels for insulin therapy were 80--149 mg/dl. Dysglycemic events were defined as follows: ranges above 149 mg/dl represented moderate hyperglycemia, and glucose levels above 179 mg/dl represented severe hyperglycemia. Moderate hypoglycemia was defined in a range from 41 to 70 mg/dl, and severe hypoglycemia as ≤40 mg/dl \[[@CR11], [@CR20]\]. Due to general ICU routine, nurses took blood samples from an arterial catheter in 2- to 4-h intervals, depending on the patient's condition. In the absence of an arterial line, blood was collected from a central or peripheral venous catheter. Blood glucose was determined by glucose oxidase reaction using a Radiometer ABL 800 FLEX (Copenhagen, Denmark) blood gas analyzer. Depending on the identified blood glucose value, the nursing staff regulated the intravenous insulin therapy according to the local insulin protocol (Additional file [1](#MOESM1){ref-type="media"}: Table S1). All patient data, including blood gas analyses, were documented within the patient data management system (PDMS).

CGM sensor {#Sec5}
----------

According to manufacturer's information, the sensors of the interstitial CGM device consist of four independently working electrodes, which are embedded in two cannulas. This multisensory system provides enhanced signal stability and accuracy in critically ill patients. The electrodes are coated by glucose oxidase. In the enzymatic reaction, electrons are released and create an electrical gradient, which is proportional to the interstitial glucose concentration. Based on the electrical signal, the CGM algorithm calculates out of the four data signals one blood glucose value, which is displayed on a bed-sided monitor. The device provides one real-time glucose measurement per minute, with an insignificant lag time for signal processing, for up to 72 h (for more details, see Additional file [1](#MOESM1){ref-type="media"}: CGM Device).

Study procedure {#Sec6}
---------------

We inserted the sensors into the subcutaneous tissue of patient's upper leg. After initialization, the sensors required one initial blood glucose entry, followed by two further calibrations after the first and second running hour. Subsequently, the study team performed calibrations every 8 h, as proposed by the manufacturer. The ward staff were not required to perform further calibrations. We instructed nurses to observe the continuous glucose trend line and perform blood glucose measurements to adapt insulin therapy in case of excursions above or below the target range (defined in the local insulin protocol Additional file [1](#MOESM1){ref-type="media"}: Table S1). Glucose values determined by the blood gas analyzer were used as reference. Blood glucose measurements used for initial calibrations and calibrations after data gaps (\>15 min) were excluded from the point accuracy analysis. Further blood glucose measurements were included and compared to the latest CGM value immediately before calibration. As specified in the study protocol (Fig. [1](#Fig1){ref-type="fig"}), the accuracy analysis required a minimum monitoring time of 48 h or at least 12 comparative readings.Fig. 1Study procedure. We included *n* = 20 patients during 57 days of recruiting. One patient was excluded from the accuracy analysis due to a lack of comparative blood glucose samples. Ten patients required a second sensor to achieve the minimum number of comparative samples or a minimum running time of 48 h. We used an optional second sensor in one patient

Analysis criteria {#Sec7}
-----------------

Figure [2](#Fig2){ref-type="fig"} illustrates detailed endpoints for the analysis of reliability, feasibility, nurse acceptance, accuracy and potential benefits of CGM. The analysis is based on the 2013 consensus recommendations, published by Finfer et al. defining criteria for continuous glucose control in critically ill patients \[[@CR20]\]. Desirable reliability criteria include a continuous data display during \>95 % of time and device-related data gaps \<30 min \[[@CR20]\]. We calculated frequency of data gaps and analyzed the gaps subdivided as very brief (\<15 min), brief (15--30 min), prolonged (\>30 min) and very prolonged (\>2 h), so as to better describe the clinical significance of the missing trend data. The feasibility analysis considered the capacity of the device to perform within the busy ICU setting. This was supplemented by a survey of nurse acceptance assessed by brief questionnaires given to the nurses in charge of each shift (Additional file [1](#MOESM1){ref-type="media"}: Fig. S3). To determine accuracy, sensor values were compared to the simultaneously recorded blood glucose values from PDMS. We calculated point accuracy according to criteria specified within the consensus recommendations \[[@CR20]\], which can be summarized as followsFig. 2Analysis criteria. Detailed criteria for the evaluation of subcutaneous CGM in the ICU98 % of device readings should be within 12.5 % of a reference standard (or within ±10 mg/dl for readings \<100 mg/dl)The remaining 2 % of readings should be within 20 % of a reference standardMean absolute relative difference (MARD) should be \<14 % (M)ARD = │(blood glucose − sensor glucose)│/blood glucose × 100MARD \> 18 % represents poor accuracy.

In addition, we analyzed possible confounding factors on MARD, such as arterial pO~2~, temperature, hemoglobin, potassium, lactate, pH value, sequential organ failure assessment (SOFA) Score, systemic inflammatory response syndrome (SIRS), history of diabetes, blood glucose variability and glucose ranges (\<80 mg/dl, 80--179 mg/dl, \>179 mg/dl). We retrospectively calculated MARD after time-shifting the reference a fixed amount (1 up to 30 min), so as to investigate a time delay as a possible confounding factor. To investigate potential benefits of CGM in our ICU, we report glycemic control achieved with CGM compared to that achieved with intermittent glucose monitoring. This was accomplished by performing intra-individual analyses, longitudinal and parallel, of factors such as mean blood glucose level, blood glucose variability, number of dysglycemia events and time in blood glucose target range (Fig. [2](#Fig2){ref-type="fig"}). Glycemic variability was determined using standard deviation of blood glucose and glycemic lability index (Table [4](#Tab4){ref-type="table"}b), as a time-weighted index \[[@CR21]\]. To evaluate safety, we reported local complications and discussed patient risks due to inaccurate CGM measurements in a safety statement.

Statistical analysis {#Sec8}
--------------------

Results were shown as median with interquartile range or as absolute numbers with percentages. Clinical accuracy was illustrated using Bland--Altman plot \[[@CR22]\], Clarke error grid \[[@CR23]\] and Surveillance Error-Grid \[[@CR24]\]. We calculated glycemic lability index using EasyGV© software \[[@CR21]\]. Nonparametric tests were performed (Mann--Whitney *U* Test, Wilcoxon Test, Kruskal--Wallis Test, Friedman Test and Spearman's correlation). We used IBM© SPSS© Statistics version 21, Microsoft Excel© ^2010^ and R for the statistical analysis.

Results {#Sec9}
=======

We included 20 critically ill patients in this prospective trial using a total of 31 sensors (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} shows patient characteristics. In total, the device generated 68655 (1144.3 h) real-time glucose values during 1337.1 h of monitoring. The median monitoring time per patient was 70.5 h \[57.2/72.7\]. For the accuracy comparison, we collected 532 blood glucose values in 19 patients, of which 475 (89.3 %) were obtained from arterial and 57 (10.7 %) from venous catheters. There was no significant difference in accuracy between the 475 arterial blood glucose values compared to all 532 glucose values (*p* = .799). Table [2](#Tab2){ref-type="table"} shows a summary of glycemic control metrics.Table 1Patient characterizationAge61 \[54/69\]Gender (female/male)14 (70 %)/6 (30 %)BMI (kg/m^2)^23 \[22/26\]Diagnosis leading to ICU stay ARDS (ECMO, ECLA)6 (30 %) ARDS (without ECMO, ECLA)8 (40 %) Mediastinitis1 (5 %) Peritonitis3 (15 %) Intracranial hemorrhage1 (5 %) Polytrauma1 (5 %)At least one event of SIRS or sepsis during CGM20 (100 %)Sequential organ failure assessment (SOFA) Score at inclusion8 \[4/10\]Acute physiology and chronic health evaluation (APACHE) 2 Score at admission24 \[19/28\]History of diabetes mellitus5 (25 %)Administration of intravenous insulin therapy during CGM14 (70 %)Administration of vasopressors during CGM7 (35 %)Mean dose of epinephrine during sensor running time (µg/kg/min) (in seven patients receiving vasopressors)0.08 \[0.03/0.14\]Mortality during ICU stay4 (20 %)*n* = 20 patientsResults are expressed as median with interquartile range or as absolute numbers with percentages of *n* = 20 patients*BMI* body mass index, *ARDS* acute respiratory distress syndrome, *ECMO* extracorporeal membrane oxygenation, *ECLA* extracorporeal lung assist, *SIRS* systemic inflammatory response syndrome, *SOFA* sequential organ failure assessment, *APACHE* acute physiology and chronic health evaluation, *ICU* intensive care unit, *CGM* continuous glucose monitoringTable 2Mean glucose level, glycemic variability and glycemic eventsReference blood glucoseComparative CGM readingNumber of comparative glucose readings532532Readings per patient28 \[18/34\]28 \[18/34\]Mean glucose level per patient (mg/dl)133.8 \[128.4/147.5\]133.7 \[124.3/150.1\]\*Glucose variability per patient measured in SD (mg/dl)24.8 \[19.9/35.2\]32.5 \[25.2/42.2\]^§^Glycemic events: number and percentage of *n* = 19 patients Severe hypoglycemia (≤40 mg/dl)1 (5.3 %)1 (5.3 %) Moderate hypoglycemia (41--70 mg/dl)1 (5.3 %)10 (52.6 %) Euglycemia (71--149 mg/dl)19 (100 %)19 (100 %) Moderate hyperglycemia (150--179 mg/dl)18 (94.7 %)19 (100 %) Severe hyperglycemia (\>179 mg/dl)15 (78.9 %)11 (57.9 %)Glycemic events: number and percentage of *n* = 532 readings158 (29.7 %)188 (35.3 %) Severe hypoglycemia (≤40 mg/dl)1 (0.2 %)1 (0.2 %)Chi-square test: *p* \< 0.001 for crosstabulation see supplement Moderate hypoglycemia (41--70 mg/dl)2 (0.4 %)15 (2.8 %) Euglycemia (71--149 mg/dl)374 (70.3 %)344 (64.7 %) Moderate hyperglycemia (150--179 mg/dl)96 (18.0 %)101 (19 %) Severe hyperglycemia (\>179 mg/dl)59 (11.1 %)71 (13.3 %)*n* = 19 patientsResults are expressed as median with interquartile range or as absolute numbers with percentages*SD* standard deviation\* *p* = 1.0; ^§^ *p* = 0.002

Reliability, feasibility and safety {#Sec10}
-----------------------------------

The reliability analysis showed a real-time data display during 32.5 h (16/62.4) per sensor, which is 45.1 % of the expected time of 72 h and 84.8 % of the 37.9 h actual monitoring time. During 80223 min (1337.1 h) of monitoring, we observed in total 11568 min (192.8 h) of missing values. The number of data gaps was 155, of which 68 (43.9 %) were very brief (\<15 min), 35 (22.6 %) were brief (15--30 min), 27 (17.4 %) were prolonged (30--120 min) and 25 (16.1 %) were very prolonged. The sensor insertion itself was easily performed and required less than 10 min. The complication rate at the site was low. Minor bleeding after insertion occurred in four patients. We observed no local infection. The main feasibility issue was premature sensor removal. Detailed device reliability and feasibility is shown in Table [3](#Tab3){ref-type="table"}.Table 3Reliability and feasibilityPer sensorInitialization time27 minTotal time until first displayed value37.5 min \[36/42\]Expected monitoring time after initialization72 hActual monitoring time after initialization37.9 h \[23/71.3\] Real-time data display32.5 h \[16/62.4\] Percentage of real-time data display/expected monitoring time after initialization45.1 % Percentage of real-time data display/actual monitoring time after initialization84.8 % \[67.9/93.8\]Data gaps after initialization5 h \[1.9/8.3\] Percentage of data gaps/actual monitoring time after initialization15.2 % \[6.2/32.1\] Number of performed calibrations9.5 \[6/13\]Reasons for the 11,568 min (192.8 h) of data gapsPercentage of data gaps 11,568 min (192.8 h)Percentage of monitoring time 80,223 min (1337.1 h)1 Poor sensor signal (%)23.33.42 Sensor failure (%)15.02.23 Processor line error (%)10.91.64 Disconnection (%)15.62.35 Pending after reconnection (%)3.40.56 Calibration required (%)27.84.07 Others (%)4.00.6Device-related reasons (1--3) (%)49.27.2Not device related (4--7) (%)50.87.4Reasons for 21 prematurely sensor removalsNumber of sensorsPercentage of all sensors (%)Percentage of removed sensors (%)Sensors 72 h completed1032.3--Sensors removed prematurely2167.71001 Accidentally722.633.32 Poor sensor signal during measurement722.633.33 Poor sensor signal immediately after initialization13.24.84 MRI13.24.85 Discharge13.24.86 Death26.59.57 Others26.59.5Device-related reasons (1--3)1548.471.4Not device related (4--7)619.428.6*n* = 20 patients, 31 sensorsResults are expressed as median with interquartile range or as absolute numbers with percentages*MRI* magnetic resonance imaging

Nurse acceptance {#Sec11}
----------------

The nurses received 128 questionnaires during the CGM monitoring period. The response rate was one-third (*n* = 43, 34 %). The majority (79.1 %) of the nursing staff rated the device as not beneficial in the daily ICU routine. Advantages, such as the opportunity to observe glucose trends, were reported in 20.9 % of the questionnaires. Disadvantages were described by 53.5 %. Reasons included the inadequate alarm performance (23.3 %), the additional device (23.3 %) and device line (6.9 %) as disturbing factors during bedding and mobilization in the ICU routine.

Point accuracy {#Sec12}
--------------

60.3 % of sensor data were within 12.5 % from the reference blood glucose (or were within ±10 mg/dl for readings \<100 mg/dl). In total, 76.9 % of sensor readings were within 20, and 23.1 % deviated more than 20 % from the reference. MARD was 15.3 % (95 % CI 13.5--17.0 %). Spearman's correlation coefficient was 0.688, *p* \< .001, *r*^2^ = 0.461. The Bland--Altman plot (Fig. [3](#Fig3){ref-type="fig"}a) showed a mean bias of 0.53 mg/dl and limits of agreement of +64.6 mg/dl and −63.5 mg/dl. Clarke error grid and Color-Coded Surveillance Error-Grid (Fig. [3](#Fig3){ref-type="fig"}b, c) showed potentially dangerous errors. Additional file [1](#MOESM1){ref-type="media"}: Table S2 shows the detection of dysglycemic events.Fig. 3Bland--Altman plot, Clarke error grid, Color-coded Surveillance Error-Grid. *n* = 532 comparative samples. **a** Bland--Altman plot. The mean bias indicates whether there is a systematic error. Upper and lower limits were calculated by mean bias ±1.96 × standard deviation of the difference between BG and sensor glucose and represent random variations around the mean bias. If there is a Gaussian distribution, 95 % of points are located between these limits. \[[@CR22], [@CR41]\]. **b** Clarke error grid. Distribution: *A* = 76.9 %, *B* = 21.6 %, *C* = 0.2 %, *D* = 0.9 %, *E* = 0.4 %. Zones A (CGM data ≤20 % deviation from BG) and *B* are considered as clinically acceptable zones, whereas values in zones *C*, *D* and *E* are increasingly dangerous for the patient, and zone *E* may lead to adverse therapeutic decisions. \[[@CR23]\]. **c** Color-coded Surveillance Error-Grid. The Surveillance Error-Grid software is available at <http://www.diabetestechnology.org/SEGsoftware/Surveillance-Error-Grid-Analysis.xlsm>. Last Accessed: Dec 11 2015 \[[@CR24]\]

Confounding factors on accuracy {#Sec13}
-------------------------------

We identified that the blood glucose variability, analyzed in standard deviation, was significantly associated with CGM accuracy (Fig. [4](#Fig4){ref-type="fig"}a). Confirming this finding, standard deviation per patient was positively correlated with MARD per patient *k* = 0.593, *p* = .001, *n* = 19, *r*^2^ = 0.298 (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1). MARD deteriorated in the hyperglycemic blood glucose range (Fig. [4](#Fig4){ref-type="fig"}a). There was no significant improvement or deterioration of MARD after time-shifting the reference glucose a fixed amount of 1 up to 30 min (Additional file [1](#MOESM1){ref-type="media"}: Fig. S2). MARD was worse during application of vasoconstrictors (Additional file [1](#MOESM1){ref-type="media"}: Table S3a). Previously known diabetes mellitus and episodes of SIRS did not confound MARD (Additional file [1](#MOESM1){ref-type="media"}: Table S3a). The severity of disease, measured via SOFA Score, showed a minor positive correlation with the MARD (*k* = 0.088, *p* = .043, *r*^2^ = 0.006, *n* = 532). There was no significant correlation of arterial pO2, temperature, pH value, lactate, hemoglobin, or potassium and MARD (Additional file [1](#MOESM1){ref-type="media"}: Table S3b).Fig. 4Confounding factors on MARD. **a** (*left*): Association between MARD and individual daily blood glucose variability shown in first and second standard deviation of reference glucose. *First boxplot* The CGM device shows acceptable accuracy\* (MARD median 10.9 %) if the blood glucose variability is low (first standard deviation). *Second boxplot* Accuracy deteriorates (MARD median 24 %) during increased blood glucose variability (second standard deviation). **b** (*right*): Association between MARD and blood glucose ranges. *Second boxplot* The CGM device shows acceptable accuracy\* (MARD median 8.8 %) in blood glucose ranges between 80 and 179 mg/dl. *First* and *Third boxplots* Accuracy deteriorates in the hypoglycemic range (MARD median 65.8 %) and during severe hyperglycemia (MARD median 16 %). *\*According to criteria specified within the consensus recommendations* \[[@CR20]\]*, MARD should be* \<14 %

Potential benefits of CGM in our ICU {#Sec14}
------------------------------------

In 10 patients with an ICU stay of at least nine consecutive days, the longitudinal analysis showed no significant reduction in dysglycemic events during 3 days of CGM compared to 72 h before and 72 h after CGM (Table [4](#Tab4){ref-type="table"}a). In the parallel analysis, CGM determined significantly lower minimal glucose values and detected more hyperglycemic events compared to intermittent blood glucose values in eight patients, in whom the device displayed accurate results with a MARD \< 14 % (Table [4](#Tab4){ref-type="table"}b).Table 4Potential benefits of CGM in our ICUPer patientBlood glucose 3 days before CGMBlood glucose 3 days during CGM\*Blood glucose 3 days after CGM*p* value(a) Longitudinal analysis. Blood glucose metrics before/during/after CGM. *n* = 10 patients, 998 blood glucose valuesNumber of BGA30 \[25/40\]35.5 \[28/41\]26.5 \[22/34\]*p* = .001^§^Number of hypoglycemia0 \[0/0\]0 \[0/0\]0 \[0/0\]*p* = 1.00Number of hyperglycemia3 \[1/4\]2.5 \[1/5\]2 \[1/3\]*p* = .779Time in target (in %)82.5 \[74/98.2\]81.6 \[68.9/95.6\]88.7 \[81.3/94.3\]*p* = .452Time \<71 mg/dl (in %)0 \[0/0\]0 \[0/0\]0 \[0/0\]*p* = 1.00Time \>149 mg/dl (in %)17.5 \[1.8/26\]18.4 \[4.4/31.1\]11.3 \[5.7/15.4\]*p* = .717Blood glucose min (mg/dl)89 \[80/100\]85 \[73/106\]97.5 \[85/110\]*p* = .273Blood glucose max (mg/dl)173.5 \[162/187\]202 \[159/218\]166 \[153/185\]*p* = .014^\#^Mean glucose level (mg/dl)134 \[126.1/137.1\]130.7 \[123.5/139\]128.5 \[120.6/138.4\]*p* = .497Mean glucose SD (mg/dl)18.9 \[15.8/22.4\]20.7 \[17.6/36.4\]16.2 \[11.6/24.2\]*p* = .741Per patientBlood glucose values (*n* = 239)CGM sensor glucose (*n* = 34056)*p* value(b) Parallel analysis. Comparison of intermittent blood glucose to CGM glucose metrics including the total number of CGM readings, *n* = 8 patients MARD \< 14 %, 239 blood glucose values, 32,044 CGM valuesNumber of readings29.5 \[26.5/31.5\]3975 \[3780/4109\]*p* = .012Number of hypoglycemia0 \[0/0\]0.5 \[0/2\]*p* = .066Number of hyperglycemia1 \[1/5\]7 \[6/18\]*p* = .018Time in target range (in %)88.7 \[60.7/96.5\]85.2 \[57.9/91.6\]*p* = .208Time \<71 mg/dl (in %)0 \[0/0\]0.3 \[0/2.3\]*p* = .068Time \>149 mg/dl (in %)11.3 \[3.6/39.3\]14.3 \[6.2/40.6\]*p* = .327Glucose min (mg/dl)103.5 \[87/111.5\]76 \[62/91\]*p* = .017Glucose max (mg/dl)195 \[154.5/211\]186 \[178.5/220.5\]*p* = .208Mean glucose level (mg/dl)130.2 \[124.3/147.9\]128.7 \[120.5/147.4\]*p* = .327Mean glucose SD (mg/dl)19.9 \[14.4/22.7\]20.6 \[16.5/28.4\]*p* = .093Glycemic lability index38.0 \[14/53\]36.9 \[18.5/90.7\]*p* = .674Intra-individual longitudinal and parallel analysis, target range 71--149 mg/dlResults are expressed as median with interquartile range or as absolute numbers with percentagesGlycemic lability index: time interval 1440 min = 24 h, glucose in mg/dl, sampling interval: blood glucose 120 min = 2 h, sensor glucose 1 minNumber of hypoglycemia or hyperglycemia: only events of newly developed hypoglycemia or hyperglycemia were considered in the analysis*BGA* blood glucose analysis, *SD* standard deviation, *GLI* glycemic lability index^§^Wilcoxon test before and during *p* = .123; before and after *p* = .05, during and after *p* = .005^\#^Wilcoxon test before and during *p* = .241, before and after *p* = .415, during and after *p* = .013\* BGAs during CGM data gaps and times of temporary system failure are included

Discussion {#Sec15}
==========

Reliability, feasibility and nurse acceptance {#Sec16}
---------------------------------------------

This prospective study was initially conducted with the intention of implementing a minimally invasive, simple to use CGM device in our ICU, in order to improve glycemic control. Unfortunately, application and performance were not as reliable as expected. Numerous sensors were removed prematurely, and the percentage of data gaps in relation to the expected sensor running time exceeded the time specified within the consensus recommendations of ICU experts \[[@CR20]\]. The fact that we did not demand additional calibrations from the nursing staff and that they were not involved in troubleshooting may have contributed to the extent of data gaps and the poor performance. Since 7.4 % of data gaps were not device related, the data display during 85.6 % of the sensor running time after initialization could be corrected to 93 %. The high rate of accidentally removed sensors underlines the vulnerable use of the subcutaneous device in intensive care. This is supported by the opinion of our ICU nursing staff. More experience with a device may enhance feasibility. However, device-related issues, which are not improvable by experience, occurred frequently. Recently published investigations evaluating the same device reported minimal differences in reliability, but the clinically relevant results were concordant \[[@CR17]--[@CR19]\].

Point accuracy and confounding factors {#Sec17}
--------------------------------------

The subcutaneous device did not fulfill the suggested accuracy criteria for CGM in critically ill patients, specified within the consensus recommendations of ICU experts \[[@CR20]\]. The distribution in the Clarke error grid \[[@CR23]\] was unsatisfactory, as all 532 comparative readings of this analysis should have been located in zone A or B, preferably in zone A. The Surveillance Error-Grid \[[@CR24]\], which promises to be closer to clinical routine, showed similar degrees of risk. In the Bland--Altman plot, the mean bias indicated that there was no systematic error \[[@CR22]\]. However, 95 % of the values were within 128 mg/dl of the reference glucose. These wide limits of agreement illustrated a high random error \[[@CR22]\]. The detection of dysglycemia was critical. The results considering MARD values within the 12.5 % range, and Clarke error grid and Bland--Altman plot are precisely consistent with those reported by Van Hooijdonk et al. \[[@CR17]\]. Two further studies showed slightly better accuracy of the same system \[[@CR18], [@CR19]\]. Although specifically designed for ICU use, the investigated subcutaneous device failed to achieve comparatively accurate results in all recently published trials \[[@CR17]--[@CR19]\], as opposed to the CGM technologies quantifying glucose concentration in the vascular compartment of critically ill patients \[[@CR25]--[@CR28]\]. This leads to the conclusion that, with the intention to administrate insulin therapy, the subcutaneous glucose determination is not the proper method to estimate blood glucose levels during the acute phase of severe illness.

Inaccuracies may be attributed to a physiological time delay relating to the glucose diffusion from the plasma to the interstitial compartment \[[@CR29], [@CR30]\]. In healthy humans and diabetes patients, this time delay has been observed to range from 0 to 40 min in various studies summarized by Scuffi et al. \[[@CR30]\]. Rebrin et al. found no evidence that physiological delays exceeded 5--10 min and argued that device-related processes are responsible for longer periods \[[@CR31]\]. Moreover, Boyne et al. addressed the issue of random inter-sensor time discrepancies, which were quantitatively similar to physiological time delays, when comparing measurements of two subcutaneous sensors in the same individual \[[@CR32]\]. Factors influencing the glucose diffusion rate, such as blood flow, peripheral microcirculation, and metabolic rate of subcutaneous tissue and adjacent cells, are all frequently altered in critically ill patients \[[@CR11], [@CR33]\]. We found no indication for a fixed time shift, but time delay and interstitial sensor accuracy may vary depending on the patient's condition. There is evidence to support this hypothesis, since the use of vasopressors and a higher SOFA Score downgraded sensor accuracy in the present trial. In contrast, the accuracy of a subcutaneous CGM device was significantly improved in patients with septic shock compared to patients without sepsis \[[@CR34]\]. Further studies cited that circulatory shock requiring norepinephrine therapy and impaired microcirculation had no influence on subcutaneous sensor accuracy \[[@CR35], [@CR36]\]. Variable subcutaneous oxygen concentration may interfere with the glucose oxidase. We did not investigate tissue paO2, but arterial paO2, as a correlating factor, had no clinically relevant impact on accuracy.

Glucose homeostasis is affected by the peripheral glucose uptake \[[@CR33]\]. Inflammation may lead to an insufficient GLUT 4 translocation to sarcolemmal membrane \[[@CR3]\]. This mechanism resulted in an impaired glucose supply in skeletal muscle cells in ICU patients \[[@CR3]\]. A decreased glucose uptake was observed in adipocytes of septic rats \[[@CR37]\]. We hypothesize that an insufficient GLUT 4 translocation may occur in subcutaneous tissue cells of critically ill patients. This may influence the accuracy of a subcutaneous CGM device, when compared to blood glucose. Consequently, it can still be assumed that subcutaneous CGM reflects actual insulin-dependent tissue glucose dynamics, which may be clinically relevant \[[@CR32]\].

We identified that the sensor accuracy deteriorated in patients with elevated glycemic variability, as well as in the hyperglycemic range. Unfortunately, inaccuracies of CGM occurred particularly often when the need for CGM would have been most beneficial. Delayed diffusion processes become increasingly significant during rapid glucose oscillations \[[@CR30], [@CR33]\] and may contribute to the adverse influence of glucose variability and hyperglycemia on sensor performance. In healthy volunteers, the interstitial glucose was similar to venous glucose during steady-state conditions, but an increased time delay was observed when glucose levels were rapidly elevated by glucose infusion \[[@CR38]\]. We could not confirm the findings reported by van Hooijdonk et al. that accuracy was influenced by a history of diabetes \[[@CR17]\]. As already assumed in this study, inaccuracies in critically ill diabetic patients were possibly attributable to glucose fluctuations \[[@CR17]\]. Although intravascular and interstitial space should be considered as different glucose compartments, the sensor technology requires blood glucose calibrations \[[@CR33], [@CR39]\]. This is a major concern, since sensor calibration during glucose alterations may subsequently cause and amplify inaccuracies \[[@CR33]\].

Safety statement {#Sec18}
----------------

The local complication rate was acceptable, but critical safety issues arose as a consequence of inaccurate measurements. Clarke error grid and Surveillance Error-Grid showed potentially dangerous situations for the patients. Clinicians need to be aware of the fact that this device is not safe to guide insulin therapy. Even if used only to support common glucose control, this device can lead to confusing situations in the ICU routine of glucose management. As our experience showed, clinicians should always critically question the displayed CGM data.

Potential benefits of CGM in our ICU {#Sec19}
------------------------------------

Glucose monitoring with the CGM system did not improve glycemic control in the longitudinal, intra-individual analysis. Low accuracy, as well as low nurse acceptance, may be potential reasons. Besides, the time in target of our severely ill patients with and without CGM was high. As a consequence, it may be difficult to demonstrate improved control even with a device that had reasonable accuracy. Conversely, if CGM was accurate, it showed potential benefits. In contrast to the findings of Brunner et al., glycemic variability was not significantly different when calculated from accurate continuous values as compared to less frequent blood glucose values \[[@CR40]\]. If accurate CGM systems and adapted insulin protocols are implemented in the ICU, further research is required to evaluate long-term effects on clinical outcomes in RCTs. Insulin therapy guided by CGM did not impact on time in target range and glycemic variability in previous RCTs \[[@CR13], [@CR14], [@CR40]\].

Potential areas for improvements {#Sec20}
--------------------------------

Calibration should only be performed during "steady-state" glucose levels, and not during rapid glucose fluctuations \[[@CR33], [@CR39]\] or adapted within a special calibration algorithmImproved fixation method or different localization to avoid accidental sensor removalWireless device to avoid data gaps caused by occasional disconnection during bedding or mobilization, as well as accidental removalsIntegration of the continuous glucose display into the established patient monitor to reduce additional equipmentInclusion of a suggestion according to the local insulin treatment protocol into monitor

Limitations {#Sec21}
-----------

Firstly, this was a point accuracy analysis, in which only the concurrent blood glucose sample was considered. The reporting of glucose trending is not possible in this trial. Secondly, in the clinical setting we cannot exclude that there is a delay between the taking of a blood sample and the actual analysis via blood gas analyzer, where the time-point is documented \[[@CR12], [@CR20]\]. Thirdly, not all nurses were familiar with the device after the initial instructions provided by the manufacturer. Fourthly, the low response rate to the questionnaires may bias the results of the nurse acceptance survey. Fifthly, due to the low number of actual hypoglycemic events, there is a lack of evidence to draw a conclusion concerning the accuracy during hypoglycemia. It has to be stressed that this study was not designed to evaluate potential benefits of CGM on glucose control and there was no variation to the insulin protocol.

Conclusion {#Sec22}
==========

The Medtronic System did not perform with satisfactory accuracy, feasibility or nursing acceptance when evaluated in 20 medical-surgical ICU patients. Low point accuracy and prolonged data gaps significantly limited the potential clinical usefulness of the CGM trend data. Future studies are required to determine the clinical value of the real-time Sentrino^®^ glucose trend data and alarms, using a validated nurse-driven insulin dosing algorithm in order to improve the safety and efficacy of blood glucose control in hospitalized patients.

Additional file {#Sec23}
===============

10.1186/s13613-016-0167-z Supplementary Method. CGM Device. Supplementary Tables. **Table S1.** The local insulin protocol. **Table S2.** Detection of dysglycemic events. **Table S3a.** Confounding factors on MARD. **Table S3b.** Spearman´s correlation of paO2, temperature, lactate, pH-value, hemoglobin, potassium and SOFA-Score and MARD. Supplementary Figures. **Fig. S1.** Correlation of blood glucose variability per patient and MARD per patient. **Fig. S2.** MARD after time-shifting the reference a fixed amount (1 up to 30 minutes). **Fig. S3.** Nurse questionnaire.
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